Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

Feb 1, 2014

by Sophiris Bio News Release

In: Posted Date, Publications, Published Date

Article published April, 2013
Mostafa M. Elhilali et al.

Purpose: We conducted a safety and efficacy evaluation of intraprostatic injection of PRX302, a modified pore forming protein (proaerolysin) activated by prostate specific antigen, as a highly targeted,

Read more